<DOC>
	<DOCNO>NCT00698568</DOCNO>
	<brief_summary>This study evaluate , versus placebo , safety Herpes simplex candidate vaccine adjuvant initially HSV seropositive seronegative subject genital herpes disease .</brief_summary>
	<brief_title>Safety Evaluation Herpes Simplex Candidate Vaccine ( gD2t ) With Adjuvant HSV Seropositive / Seronegative Subjects</brief_title>
	<detailed_description>This study monitor Data Safety Monitoring Board . At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 year age time first vaccination Written inform consent Females childbearing potential must negative pregnancy test enrollment prior vaccination use accepted method birth control Any previous history current clinical sign symptom genital herpes disease . Any previous vaccination herpes simplex . Any previous administration MPL . History herpetic keratitis . History erythema multiforme . Female subject pregnant , lactate plan pregnancy one month last vaccine dose Patient immunocompromised receive immunomodifying therapy kind . Topical corticoid therapy allow . HIV positive time enrollment Clinical sign acute febrile illness time entry study . Any continuous suppressive antiviral oral therapy within 6 month prior entry . Any administration immunoglobulins vaccination course within one month prior first vaccination . Any vaccine administration le one week study vaccination . Previous know hypersensitivity vaccination component vaccine . Simultaneous participation clinical trial investigational drug vaccine concurrent study period begin 30 day prior entry study 5 halflives drug Recent history alcoholism drug abuse Recent clinical history evidence significant hepatic disease History current acute chronic auto immune disease . Recent clinical history evidence renal dysfunction Lifethreatening serious cardiac ( NYHA grade IIIIV ) , gastrointestinal , haematological immunological disorder , opinion investigator , would preclude entry study . Inability unwillingness comply protocol expect complete study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Herpes simplex , Herpes simplex candidate vaccine</keyword>
</DOC>